EP1303291B1 - Peptides antitumoraux et anti-vih et fragments de lysozyme - Google Patents

Peptides antitumoraux et anti-vih et fragments de lysozyme Download PDF

Info

Publication number
EP1303291B1
EP1303291B1 EP01957109A EP01957109A EP1303291B1 EP 1303291 B1 EP1303291 B1 EP 1303291B1 EP 01957109 A EP01957109 A EP 01957109A EP 01957109 A EP01957109 A EP 01957109A EP 1303291 B1 EP1303291 B1 EP 1303291B1
Authority
EP
European Patent Office
Prior art keywords
lysozyme
hiv
fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01957109A
Other languages
German (de)
English (en)
Other versions
EP1303291A1 (fr
EP1303291A4 (fr
Inventor
Sylvia Lee-Huang
Philip L. Huang
Paul Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of EP1303291A1 publication Critical patent/EP1303291A1/fr
Publication of EP1303291A4 publication Critical patent/EP1303291A4/fr
Application granted granted Critical
Publication of EP1303291B1 publication Critical patent/EP1303291B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (6)

  1. Utilisation d'un fragment de lysozyme comprenant la séquence d'acides aminés de SEQ ID NO: 8, dans laquelle ledit fragment se compose d'une séquence de 9 à 30 résidus d'acides aminés, et dans laquelle ledit fragment comprend éventuellement une à cinq substitutions, délétions ou additions d'acides aminés présentes dans les séquences flanquant la séquence d'acides aminés de SEQ ID NO: 8, pour préparer un médicament pour le traitement d'une infection par le VIH.
  2. Utilisation selon la revendication 1, dans laquelle les substitutions comprennent une à cinq substitutions conservatrices.
  3. Utilisation selon la revendication 1, dans laquelle ledit fragment ne comprend aucune substitution, délétion ou addition.
  4. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le fragment se compose d'une séquence de 9 à 18 résidus d'acides aminés.
  5. Utilisation selon la revendication 1, dans laquelle ledit fragment se compose de la SEQ ID NO: 1.
  6. Utilisation selon la revendication 1, dans laquelle ledit fragment se compose de la SEQ ID NO: 8.
EP01957109A 2000-07-07 2001-07-09 Peptides antitumoraux et anti-vih et fragments de lysozyme Expired - Lifetime EP1303291B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21670200P 2000-07-07 2000-07-07
US216702P 2000-07-07
PCT/US2001/021582 WO2002004011A1 (fr) 2000-07-07 2001-07-09 Peptides antitumoraux et anti-vih et fragments de lysozyme

Publications (3)

Publication Number Publication Date
EP1303291A1 EP1303291A1 (fr) 2003-04-23
EP1303291A4 EP1303291A4 (fr) 2005-04-06
EP1303291B1 true EP1303291B1 (fr) 2007-10-17

Family

ID=22808164

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01957109A Expired - Lifetime EP1303291B1 (fr) 2000-07-07 2001-07-09 Peptides antitumoraux et anti-vih et fragments de lysozyme

Country Status (8)

Country Link
US (1) US7838275B2 (fr)
EP (1) EP1303291B1 (fr)
JP (1) JP2004505616A (fr)
AT (1) ATE375800T1 (fr)
AU (1) AU2001278884A1 (fr)
CA (1) CA2415083A1 (fr)
DE (1) DE60130994T2 (fr)
WO (1) WO2002004011A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002511A1 (fr) * 2002-06-28 2004-01-08 Fuso Pharmaceutical Industries, Ltd. Agent anti-hiv
ITMI20061950A1 (it) * 2006-10-11 2008-04-12 Therapicon Srl Effetto antimetastatico in condizioni patologiche delle cellule umane
CA2679939A1 (fr) * 2007-03-02 2008-09-12 Stefano Ferrari Composition et procede de traitement du virus de papillome et des sarcoides equins
US20170049863A1 (en) * 2014-02-21 2017-02-23 National University Corporation Tokyo University Of Marine Science And Technology Norovirus deactivator and method for producing same, method for deactivating norovirus, method for producing lysozyme component for norovirus deactivation use, prophylactic or therapeutic agent for norovirus infection, and external preparation for skin for norovirus deactivation purposes
WO2018123821A1 (fr) 2016-12-28 2018-07-05 Dic株式会社 Dispersion et composition d'encre pour jet d'encre, couche de conversion de lumière et élément d'affichage à cristaux liquides utilisant la dispersion
CN110438106B (zh) * 2019-08-06 2021-03-23 北京华韵国丰新材料科技有限公司 一种人工设计的纳米溶菌酶和纳米溶菌酶的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583211A (en) * 1992-10-29 1996-12-10 Beckman Instruments, Inc. Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
JPH06211692A (ja) * 1993-01-21 1994-08-02 Nippon Oil Co Ltd 免疫増強剤
EP0721458B1 (fr) 1993-09-28 2000-05-17 Beckman Coulter, Inc. Synthese de biopolymeres utilisant des polymeres organiques a surface activee
WO1997049430A1 (fr) * 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapie par modulation de la presentation d'antigenes
US6340461B1 (en) * 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
GB9907366D0 (en) 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins

Also Published As

Publication number Publication date
EP1303291A1 (fr) 2003-04-23
JP2004505616A (ja) 2004-02-26
US20050008631A1 (en) 2005-01-13
ATE375800T1 (de) 2007-11-15
US7838275B2 (en) 2010-11-23
EP1303291A4 (fr) 2005-04-06
AU2001278884A1 (en) 2002-01-21
WO2002004011A1 (fr) 2002-01-17
DE60130994D1 (de) 2007-11-29
DE60130994T2 (de) 2008-07-24
CA2415083A1 (fr) 2002-01-17

Similar Documents

Publication Publication Date Title
Upcroft et al. Drug resistance in Giardia intestinalis
CA2042569A1 (fr) Composition renfermant un facteur de croissance fibroblaste stabilise
PT1667708E (pt) Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
DE69332883T2 (de) Ptp-d unterklasse der protein tyrosin phosphatasen
EP1303291B1 (fr) Peptides antitumoraux et anti-vih et fragments de lysozyme
EP3587443A1 (fr) Utilisation de peptide dérivé d'érythropoïétine au moyen de son effet sur la prévention de la lésion cellulaire
EP0988050B1 (fr) Utilisation de l'asparaginase wolinella succinogenes pour traiter des maladies associees a la dependance de l'asparagine
EP0362209B1 (fr) Composes bioactifs synthetiques nouveaux et procede d'obtention d'effets bioactifs
WO1986006280A1 (fr) Utilisation du facteur de necrose de tumeurs comme regulateur du poids
DE69636052T2 (de) Mpl-liganden analoga
US20150337025A1 (en) Use of fusion protein
RU2404190C2 (ru) Деамидированный интерферон-бета
EP0421023B1 (fr) Enzymes catabolisantes pour l'induction du facteur de nécrose tumorale (TNF)
Karliner et al. Neonatal mouse cardiac myocytes exhibit cardioprotection induced by hypoxic and pharmacologic preconditioning and by transgenic overexpression of human Cu/Zn superoxide dismutase
JP2007536382A (ja) 放射線保護におけるｆｇｆ−２０の予防的使用および治療的使用
US4355025A (en) Biologically active amides
US4223017A (en) Biologically active amides
EP1810672A1 (fr) Utilisation vétérinaire de dérives de la pleuromutiline dans le traitement d'infections secondaires par pasteurella multocida, actinobacillus pleuropneumoniae et/ou haemophilus parasuis
Roberts The in vitro secretion of epidermal growth factor by mouse submandibular salivary gland
KR20050008762A (ko) 아시아 인종에서 피하 인터페론-베타로 ｃ형 간염의 치료
US6348444B1 (en) Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
EP2538961B1 (fr) Inhibition de la nécrose
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
US5059418A (en) Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
Kemp et al. Glycosidase activity in epididymal epithelial cells isolated from normal and α-chlorohydrin treated male rats

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030206

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050222

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/16 20060101ALI20070427BHEP

Ipc: A61K 38/04 20060101AFI20070427BHEP

Ipc: A61K 38/08 20060101ALI20070427BHEP

Ipc: A61K 38/17 20060101ALI20070427BHEP

Ipc: A61P 31/18 20060101ALI20070427BHEP

Ipc: A61K 38/10 20060101ALI20070427BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60130994

Country of ref document: DE

Date of ref document: 20071129

Kind code of ref document: P

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080117

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080128

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

26N No opposition filed

Effective date: 20080718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080709

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110727

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110706

Year of fee payment: 11

Ref country code: DE

Payment date: 20110706

Year of fee payment: 11

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120709

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120709

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60130994

Country of ref document: DE

Effective date: 20130201